Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate

Author: Benzinga Newsdesk | November 10, 2025 08:10am
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.24) by 5.26 percent. This is a 15.84 percent decrease over losses of $(1.01) per share from the same period last year. The company reported quarterly sales of $889.000 thousand which missed the analyst consensus estimate of $8.904 million by 90.02 percent. This is a 47.67 percent increase over sales of $602.000 thousand the same period last year.

Posted In: CRSP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist